High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges

References

• Rosenblatt J, Avigan D. Role of immune therapies for myeloma. J Natl Compr Canc Netw. 2015;13:1440–1447.
   PubMed Web of Science ®Google Scholar
• [Internet] Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/survival#heading-Zero.
   Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854.
   PubMed Web of Science ®Google Scholar
• Zhan F, Sawyer J, Tricot G. The role of cytogenetics in myeloma. Leukemia. 2006;20:1484–1486.
   PubMed Web of Science ®Google Scholar
• Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–2105.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Melchor L, Murison A, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015;125:831–840.
   PubMed Web of Science ®Google Scholar
• Chretien ML, Corre J, Lauwers-Cances V, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126:2713–2719.
   PubMed Web of Science ®Google Scholar
• Binder M, Rajkumar SV, Ketterling RP, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016;6:e401.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396–406.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.
   PubMed Web of Science ®Google Scholar
• Uttervall K, Duru AD, Lund J, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. 2014;9:e101819.
   PubMed Web of Science ®Google Scholar
• Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, et al. Increased serum lactate dehydrogenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymph Myeloma Leuk. 2011;11:409–413.
   PubMed Web of Science ®Google Scholar
• Terpos E, Katodritou E, Roussou M, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85:114–119.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–3387.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 1995;85:448–455.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Chee CE, Lust JA, et al. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 2011;118:2702–2707.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97:2522–2523.
   PubMed Web of Science ®Google Scholar
• Gastinne T, Leleu X, Duhamel A, et al. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol. 2007;79:297–304.
   PubMed Web of Science ®Google Scholar
• Moller HE, Preiss BS, Pedersen P, et al. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. APMIS: Acta Pathol Microbiol Immunol Scand. 2015;123:652–658.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology – an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Lacy MQ, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999;17:1551–1557.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Chung TH, Kumar S, et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2015;30:1071–1078.
   PubMed Web of Science ®Google Scholar
• Kuiper R, van Duin M, van Vliet MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126:1996–2004.
   PubMed Web of Science ®Google Scholar
• Kortum KM, Langer C, Monge J, et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol. 2015;168:507–510.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384–390.
   PubMed Web of Science ®Google Scholar
• Cifola I, Lionetti M, Pinatel E, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6:17543–17558.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Barbieri M, Manzoni M, et al. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget. 2016;7:21353–21361.
   PubMed Web of Science ®Google Scholar
• Wu SP, Pfeiffer RM, Ahn IE, et al. Impact of genes highly correlated with MMSET myeloma on the survival of non-MMSET myeloma patients. Clin Cancer Res. 2016;22:4039–4044.
   PubMed Web of Science ®Google Scholar
• Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125:1870–1876.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–3812.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127:971–976.
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12:622–635.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325–330.
   PubMed Web of Science ®Google Scholar
• Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymph. 2009;50:230–235.
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, Bredeson CN, Chang CC, et al. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol. 2003;72:274–277.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Raanani P, Yeshurun M, et al. Myeloma in scar tissue?an underreported phenomenon or an emerging entity in the novel agents' era? A single center series. Acta Haematol. 2014;132:39–44.
   PubMed Web of Science ®Google Scholar
• Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymph Myeloma Leuk. 2015;15:286–291.
   PubMed Web of Science ®Google Scholar
• Papanikolaou X, Repousis P, Tzenou T, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymph. 2013;54:1459–1464.
   PubMed Web of Science ®Google Scholar
• Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87–94.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–1767.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymph. 2013;54:1135–1141.
   PubMed Web of Science ®Google Scholar
• Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–364.
   PubMed Web of Science ®Google Scholar
• Watkins LMaCH. Multiple myeloma: diagnostic value of the blood smear. Mayo Clin Proc. 1942;17:433–440.
   Google Scholar
• Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46–55.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Dhodapkar MV, Kyle RA, et al. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer. 1993;72:108–113.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88:1780–1787.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106:2276–2279.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28:2060–2065.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Morice WG, Rajkumar V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 2014;167:500–505.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120:20–30.
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–791.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813–818.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907–912.
   PubMed Web of Science ®Google Scholar
• Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161–167.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–5782.
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673–679.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mahmood ST, Lacy MQ, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42:413–420.
   PubMed Web of Science ®Google Scholar
• Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007;13:7073–7079.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832.
   PubMed Web of Science ®Google Scholar
• Rasche L, Strifler S, Duell J, et al. The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple. Ann Hematol. 2014;93:1207–1214.
   PubMed Web of Science ®Google Scholar
• Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126:1536–1543.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940–948.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28:4630–4634.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279–3287.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib–melphalan–prednisone versus melphalan–prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448–455.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012;26:2398–2405.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013;27:2351–2356.
   PubMed Web of Science ®Google Scholar
• Chng W-J, Goldschmidt H, Dimopoulos MA, et al. Efficacy and safety of carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 study endeavor (NCT01568866). Blood. 2015;126:30–30.
   Web of Science ®Google Scholar
• Muchtar E, Gatt ME, Rouvio O, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172:89–96.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97:442–450.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–1596.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231–1238.
   PubMed Web of Science ®Google Scholar
• Brioli A, Kaiser MF, Pawlyn C, et al. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk Lymph. 2013;54:1975–1981.
   PubMed Web of Science ®Google Scholar
• Jacobus SJ, Kumar S, Uno H, et al. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011;155:340–348.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Gertz MA, Dispenzieri A, et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016;30:633–639.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100:1327–1333.
   PubMed Web of Science ®Google Scholar
• Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125:1411–1417.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375–4382.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–686.
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32:2712–2717.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28:690–693.
   PubMed Web of Science ®Google Scholar
• Jiménez-Segura R, Teruel AI, De La Rubia J, et al. Characteristics and outcome of 66 patients with extramedullary plasmacytomas (EMPs) included in a phase III pethema/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Blood. 2013;122:3188–3188.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126:391–391.
   Web of Science ®Google Scholar
• Kazmi SM, Nusrat M, Gunaydin H, et al. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clin Lymph Myeloma Leuk. 2015;15:687–693.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014;124:882–890.
   PubMed Web of Science ®Google Scholar
• Cavo M, Salwender H, Rosiñol L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from Phase European III studies. Blood. 2013;122:767–767.
   Google Scholar
• Gertz MA. When to recommend allogeneic transplant in multiple myeloma. Leuk Lymph. 2015;56:2512–2517.
   PubMed Web of Science ®Google Scholar
• Roos-Weil D, Moreau P, Avet-Loiseau H, et al. Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica. 2011;96:1504–1511.
   PubMed Web of Science ®Google Scholar
• Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016. [Epub ahead of print]. doi:10.1038/leu.2016.101.
   PubMed Web of Science ®Google Scholar
• Mayo clinic [Internet]. [cited 2016 Sept 27]. Available from: https://www.msmart.org/about.html.
   Google Scholar
• Muchtar E, Dingli D, Kumar S, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. 2016. [Epub ahead of print]. doi:10.1038/bmt.2016.174.
   Web of Science ®Google Scholar
• O'Donnell EK, Laubach JP, Yee AJ, et al. A phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2015;126:4217–4217.
   Google Scholar
• Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29:2039–2049.
   PubMed Web of Science ®Google Scholar
• From clinicaltrials.gov [Internet]. [cited 2016 Sept 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01668719?term=NCT01668719&rank=1.
   Google Scholar
• From clinicaltrials.gov [Internet]. [cited 2016 Sept 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02465060?term=Molecular+Analysis+for+Therapy+Choice&rank=1.
   Google Scholar